Plus, news about Sequentia Biotech:
CSPC, Alphamab Oncology ink ADC deal: CSPC Pharmaceutical’s JMT-Bio Technology said it will pay RMB 400 million ($57 million) upfront and up to RMB 3.08 billion ($439 million) in total for access in China to Alphamab’s anti-HER2 bispecific ADC, called JSKN003.
Visen files for IPO in Hong Kong: The six-year-old company on Monday filed to go public on the Hong Kong Stock Exchange. The Shanghai-based drug developer is working to get Ascendis’ FDA-approved pediatric growth hormone deficiency drug greenlit in China.
Sequentia Biotech raises €10M: The Spanish bioinformatics company nabbed the Series A from Seventure Partners and EIC Fund.